Intercept Pharmaceuticals (NASDAQ:ICPT) reported Q1 2018 earnings this Morning, coming in at ($3.22) per share, beating Wall Street’s estimates of ($3.37) per Share. Revenue for the quarter came in at $35.96 million missing the streets estimates of $38.44 million Recent Insider Trading for Intercept Pharmaceuticals (NASDAQ:ICPT)
- On 4/9/2018 Francesco Micheli, Major Shareholder, bought 390,625 with an average share price of $64.00 per share and the total transaction amounting to $25,000,000.00.
- On 4/9/2018 Keith Michael Gottesdiener, Director, bought 1,171 with an average share price of $64.00 per share and the total transaction amounting to $74,944.00.
- On 4/9/2018 Mark Pruzanski, CEO, bought 7,812 with an average share price of $64.00 per share and the total transaction amounting to $499,968.00.
- On 10/2/2017 David Shapiro, CMO, sold 349 with an average share price of $58.90 per share and the total transaction amounting to $20,556.10.
- On 10/2/2017 Mark Pruzanski, CEO, sold 1,532 with an average share price of $58.87 per share and the total transaction amounting to $90,188.84.
- On 10/2/2017 Rachel Mcminn, Insider, sold 283 with an average share price of $58.89 per share and the total transaction amounting to $16,665.87.
Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Recent Trading for Intercept Pharmaceuticals (NASDAQ:ICPT) Shares of Intercept Pharmaceuticals closed the previous trading session at 69.57 down -0.76 1.08% with 68.83999633789062 shares trading hands.